Retraction

‘First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset’ by Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta.¹

The above article from Cancer Science, first published on 14 September 2020 in Wiley Online Library (wileyonlinelibrary.com) and in Volume 111, pp. 4480‐4489, has been retracted by agreement between the authors, the journal Editor in Chief Masanori Hatakeyama, and John Wiley & Sons Ltd. The retraction has been agreed due to the corrections requested by the authors being too numerous and extensive to be addressed through the publication of a corrections article for the original article which the authors acknowledge would be better handled via a revised submission and peer‐reviewed version of the original article.